A revolutionary immunotherapy approach is flipping cancer's greatest strength against itself: instead of attacking tumors from the outside, researchers are reprogramming cancer cells to become immune sentinels that alert the body to danger. This innovation, which earned the 2026 BioInnovation Institute and Science Prize for Innovation, addresses a critical gap in cancer treatment. While checkpoint inhibitors and CAR-T cell therapies have transformed outcomes for some patients, they only work for a minority due to tumor progression, heterogeneity, and immune evasion .

How Does This New Immunotherapy Approach Work?

The strategy, developed by Fábio Rosa and his team at Asgard Therapeutics, uses a technique called in vivo immune cell reprogramming. Rather than extracting cells for expensive laboratory processing, the therapy works directly inside the patient's body. Rosa's team discovered that three specific transcription factors, which are proteins that control gene expression, can reprogram ordinary tumor cells into conventional type 1 dendritic cells, or cDC1 cells . These are rare immune cells crucial for initiating anti-tumor immunity.

"Cancer cells are very good at hiding from the immune system, and what we aim to do is change that behavior," Rosa explained. "Instead of trying only to attack the tumor from the outside, we give cancer cells new instructions so they start acting like immune cells that alert the body to danger" .

"Many patients do not respond to immunotherapies due to insufficient immune activation within tumors. Our approach addresses this by inducing antigen presentation directly in the tumor microenvironment," said Rosa.

Fábio Rosa, Researcher at Asgard Therapeutics

Once reprogrammed, these transformed tumor cells trigger powerful immune attacks from within. In animal models, the approach reprogrammed tumor cells in place, increased T-cell infiltration, expanded tumor-reactive T cells, and led to complete tumor regression, especially when combined with existing checkpoint blockade immunotherapies .

Why Does This Matter for Patients Who Don't Respond to Current Treatments?

Current immunotherapies like checkpoint inhibitors and CAR-T cells have revolutionized cancer treatment for some patients, but they have a significant limitation: they only work for a minority of people. The reasons are complex. Tumors evolve and change over time, they're genetically diverse, and they've developed sophisticated ways to hide from the immune system. This new approach tackles the problem differently by working from inside the tumor itself .

The key advantage is that it doesn't require the expensive, time-consuming process of extracting cells, growing them in the laboratory, and reinfusing them back into patients. Instead, the therapy can be delivered directly to tumors, potentially making it faster, more affordable, and accessible to more patients. This in vivo approach eliminates costly and slow cell culture steps, expanding both availability and efficacy of cancer immunotherapy .

What Do Early Results Show?

The research published in Science in April 2026 demonstrates that cells can be reprogrammed to take on entirely new identities. While this approach has been widely explored in regenerative medicine to produce neurons, heart cells, liver cells, and macrophages, its ability to reprogram cells into cells that orchestrate immune responses has remained largely untapped until now .

In animal models, the results were striking. The reprogrammed cells not only adopted the identity and behavior of key immune sentinels but also triggered powerful anti-tumor responses in living systems. When combined with checkpoint blockade immunotherapies, the approach led to complete tumor regression .

Steps to Bringing This Therapy to Patients

• Laboratory Development: Rosa and his colleagues pioneered cell reprogramming approaches to generate rare and functionally specialized immune cells from unrelated, easily accessible cell types, identifying the specific trio of transcription factors needed for reprogramming.
• Animal Model Testing: The team demonstrated that reprogrammed tumor cells increased T-cell infiltration, expanded tumor-reactive T cells, and led to complete tumor regression, particularly when combined with existing checkpoint blockade immunotherapies.
• Clinical Trial Planning: Rosa's team at Asgard Therapeutics is aiming to submit a clinical trial application in 2027 to bring their therapy to the clinic, marking the transition from laboratory research to human testing.

The path forward requires more than just scientific innovation. According to Rosa, achieving widespread benefit will require continued scientific innovation, supportive healthcare systems, forward-looking policies, and active patient participation in research and clinical trials .

"We are in a period of real progress in cancer treatment, where targeting the immune system can drive long-term benefit and even cures for some patients. The goal now is to extend this benefit to more patients, ideally making these outcomes the norm rather than the exception," said Rosa.

Fábio Rosa, Researcher at Asgard Therapeutics

What Makes This Innovation Stand Out in the Immunotherapy Landscape?

The BioInnovation Institute Prize recognizes scientists who conduct research at the intersection of life sciences and entrepreneurship. Rosa's work exemplifies this intersection by combining cutting-edge molecular biology with a practical, scalable approach to treatment delivery .

Michael Funk, senior editor at Science, highlighted the significance: "Dr. Rosa's work has enabled genetic reprogramming of various cancer cell types such that these cells activate the immune system and bring about their own destruction. Using tools from gene therapy, his team is now working on therapeutic treatments that can achieve this reprogramming inside patients in order to eliminate costly and slow cell culture steps and thus expand availability and efficacy of cancer immunotherapy" .

The innovation addresses a fundamental challenge in cancer treatment: heterogeneity and immune evasion. By converting tumors into their own vaccine factories, the approach potentially works against multiple cancer types and could overcome the resistance mechanisms that limit current therapies .

While the clinical trial application is planned for 2027, this research represents a significant shift in how scientists think about cancer immunotherapy. Rather than viewing tumors solely as enemies to be attacked from outside, researchers are now exploring ways to reprogram cancer cells themselves into agents of their own destruction. For patients who haven't benefited from existing immunotherapies, this approach offers genuine hope for a new treatment option that could finally extend the benefits of immunotherapy to everyone .